Chronic HBV infection outside treatment guidelines: is treatment needed?
Antivir. Ther. (Lond.)., Aug (2012)
Society of interventional radiology critique and commentary on the cochrane report on transarterial (chemo)embolisation.
Hepatology., Aug (2012)
Acute liver failure in adults: an evidence-based management protocol for clinicians.
Gastroenterol Hepatol (N Y)., Mar;8(3):161-212 (2012)
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Clin. Gastroenterol. Hepatol., Aug;10(8):941-6; quiz e68 (2012)
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol., Apr;6(2):173-85 (2012)
Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action.
J. Gastroenterol. Hepatol., Feb;27(2):238-47 (2012)
The NS5A replication complex inhibitors: difference makers?
Clin Liver Dis., Aug;15(3):627-39 (2011)
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.
AIDS Res Ther., 8:29 (2011)
Hepatocellular carcinoma: molecular and genomic guideline for the clinician.
Clin Liver Dis., May;15(2):307-21, vii-x (2011)
RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study.
Antivir. Ther. (Lond.)., 16(4):547-54 (2011)
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol., Sep;8(9):2 p preceding 4-15 (2010)
Is chronic hepatitis B being undertreated in the United States?
J. Viral Hepat., Jun;18(6):377-83 (2011)
Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic.
J. Viral Hepat., Apr;18(4):e40-51 (2011)
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
J. Clin. Gastroenterol., Sep;45(8):733-7 (2011)
Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Gastroenterol Hepatol (N Y)., Sep;6(9 Suppl 16):1-16 (2010)
A multidisciplinary approach to the management of hepatocellular carcinoma.
Gastroenterol Hepatol (N Y)., Mar;6(3 Suppl 6):1-16 (2010)
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
J. Hepatol., Jan;52(1):32-8 (2010)
Diagnosis of chronic hepatitis B and the implications of viral variants and mutations.
Am. J. Med., Dec;121(12 Suppl):S12-21 (2008)
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.
Hepatol Int., Sep;3(3):480-9 (2009)
To "be" or not to "be": that is the question.
Am. J. Gastroenterol., Aug;104(8):1948-52 (2009)